{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:38:29Z","timestamp":1778542709672,"version":"3.51.4"},"reference-count":25,"publisher":"Pharmaceutical Society of Japan","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,1,24]]},"DOI":"10.1248\/bpb.b24-00435","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T22:14:11Z","timestamp":1737670451000},"page":"33-38","source":"Crossref","is-referenced-by-count":1,"title":["Actual Use of Budesonide Enteric-Coated Capsules for Crohn\u2019s Disease in Japan: Analysis of Health Insurance Big Data"],"prefix":"10.1248","volume":"48","author":[{"given":"Keiji","family":"Yagisawa","sequence":"first","affiliation":[{"name":"Graduate School of Life Science, Hokkaido University, Kita 10, Nishi 8, Kita-ku, Sapporo 060\u20130810, Japan"},{"name":"Department of Pharmacy, Sapporo-Higashi Tokushukai Hospital, 3\u20131 Kita 33, Higashi 14, Higashi-ku, Sapporo 065\u20130033, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuhito","family":"Kubota","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, 1757 Kanazawa, Tobetsu-cho, Ishikari-gun, Hokkaido 061\u20130293, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shungo","family":"Imai","sequence":"additional","affiliation":[{"name":"Keio University Faculty of Pharmacy, 1\u20135\u201330 Shibakoen, Minato-ku, Tokyo 105\u20138512, Japan"},{"name":"Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Nashimoto","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Sato","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Kashiwagi","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuo","family":"Maemoto","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, Sapporo Higashi Tokushukai Hospital, Kita 33, Higashi 14, Higashi-ku, Sapporo 065\u20130033, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Sugawara","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"},{"name":"Department of Pharmacy, Hokkaido University Hospital, Kita 14, Nishi 5, Kita-ku, Sapporo 060\u20138648, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoh","family":"Takekuma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital, Kita 14, Nishi 5, Kita-ku, Sapporo 060\u20138648, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn\u2019s disease. <i>Lancet<\/i>, <b>389<\/b>, 1741\u20131755 (2017).","DOI":"10.1016\/S0140-6736(16)31711-1"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Nakase H, Uchino M, Shinzaki S, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. <i>J. Gastroenterol.<\/i>, <b>56<\/b>, 489\u2013526 (2021).","DOI":"10.1007\/s00535-021-01784-1"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Torres J, Bonovas S, Doherty G, et al. ECCO Guidelines on therapeutics in Crohn\u2019s disease: medical treatment. <i>J. Crohns Colitis<\/i>, <b>14<\/b>, 4\u201322 (2020).","DOI":"10.1093\/ecco-jcc\/jjaa043"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Yokoyama T, Ohta A, Motoya S, Takazoe M, Yajima T, Date M, Nii M, Nagy P, Suzuki Y, Hibi T. Efficacy and safety of oral budesonide in patients. with active Crohn\u2019s disease in Japan: a multicenter, double-blind, randomized, parallel-group phase 3 study. <i>Inflamm. Intest. Dis.<\/i>, <b>2<\/b>, 154\u2013162 (2018).","DOI":"10.1159\/000484047"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Edsb\u00e4cker S, Andersson T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn\u2019s disease. <i>Clin. Pharmacokinet.<\/i>, <b>43<\/b>, 803\u2013821 (2004).","DOI":"10.2165\/00003088-200443120-00003"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Edsb\u00e4cker S, Bengtsson B, Larsson P, Lundin P, Nilsson A, Ulmius J, Wollmer P. A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules. <i>Aliment. Pharmacol. Ther.<\/i>, <b>17<\/b>, 525\u2013536 (2003).","DOI":"10.1046\/j.1365-2036.2003.01426.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Suzuki Y, Motoya S, Takazoe M, Kosaka T, Date M, Nii M, Hibi T. Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn\u2019s disease: a multicentre, double-blind, randomized, parallel-group Phase II study. <i>J. Crohns Colitis<\/i>, <b>7<\/b>, 239\u2013247 (2013).","DOI":"10.1016\/j.crohns.2012.06.006"},{"key":"8","unstructured":"8) Zentacort Capsules 3 mg package insert. Zeria Pharmaceutical Co., Ltd., Aug 2020."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Arntzenius A, van Galen L. Budesonide-related adrenal insufficiency. <i>BMJ Case Rep.<\/i>,  <b>2015<\/b>, bcr2015212216 (2015).","DOI":"10.1136\/bcr-2015-212216"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Jones W, Chastain CA, Wright PW. Iatrogenic cushing syndrome secondary to a probable interaction between voriconazole and budesonide. <i>Pharmacotherapy<\/i>, <b>34<\/b>, e116\u2013e119 (2014).","DOI":"10.1002\/phar.1432"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Yeoh SW. Iatrogenic Cushing syndrome from interaction between ritonavir and oral budesonide during direct acting antiviral hepatitis C therapy. <i>J. Clin. Exp. Hepatol.<\/i>, <b>6<\/b>, 246\u2013249 (2016).","DOI":"10.1016\/j.jceh.2016.05.006"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Colpitts L, Murray TB, Tahhan SG, Boggs JP. Iatrogenic Cushing syndrome in a 47-year-old HIV-positive woman on ritonavir and inhaled budesonide. <i>J. Int. Assoc. Provid. AIDS Care<\/i>, <b>16<\/b>, 531\u2013534 (2017).","DOI":"10.1177\/2325957417736612"},{"key":"13","unstructured":"13) Japan Medical Data Center. &lt;https:\/\/www.jmdc.co.jp\/en\/&gt;, accessed 1 June, 2024."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Umemura S, Arima H, Arima S, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019). <i>Hypertens. Res.<\/i>, <b>42<\/b>, 1235\u20131481 (2019).","DOI":"10.1038\/s41440-019-0284-9"},{"key":"15","unstructured":"15) UpToDate. \u201cCytochrome P450 3A (including 3A4) inhibitors and inducers.\u201d: &lt;https:\/\/www.uptodate.com\/contents\/image\/print?imageKey=CARD%2F76992&gt;, accessed 1 December, 2022."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) De Maeyer F, Lapauw B, Hoorens A, Geerts A, Van Vlierberghe H, Verhelst X. Secondary adrenal insufficiency after treatment with budesonide for autoimmune hepatitis. <i>Case Rep. Gastroenterol.<\/i>, <b>12<\/b>, 597\u2013601 (2018).","DOI":"10.1159\/000492204"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Wildt S, Munck LK, Becker S, Brockstedt H, Bonderup OK, Hitz MF. Risk of osteoporosis in microscopic colitis. <i>Postgrad. Med.<\/i>, <b>130<\/b>, 348\u2013354 (2018).","DOI":"10.1080\/00325481.2018.1441579"},{"key":"18","unstructured":"18) Japan Intractable Diseases Information Center. &lt;https:\/\/www.nanbyou.or.jp&gt;, accessed 1 December, 2022."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Masui S, Yonezawa A, Momo K, Nakagawa S, Itohara K, Imai S, Nakagawa T, Matsubara K. Infliximab treatment persistence among Japanese patients with chronic inflammatory diseases: a retrospective Japanese claims data study. <i>Biol. Pharm. Bull.<\/i>, <b>45<\/b>, 323\u2013332 (2022).","DOI":"10.1248\/bpb.b21-00906"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Yokoyama K, Yamazaki K, Katafuchi M, Ferchichi S. A retrospective claims. database study on drug utilization in Japanese patients with Crohn\u2019s disease treated with adalimumab or infliximab. <i>Adv. Ther.<\/i>, <b>33<\/b>, 1947\u20131963 (2016).","DOI":"10.1007\/s12325-016-0406-6"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Takeyama E, Wada H, Sato S, Tomooka K, Ikeda A, Tanigawa T. Association of. diagnostic delay with medical cost for patients with Crohn\u2019s disease: a Japanese claims-based cohort study. <i>JGH Open<\/i>, <b>5<\/b>, 568\u2013572 (2021).","DOI":"10.1002\/jgh3.12534"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Stockbrugger RW, Schoon E, Bollani S, Israeli E, Persson T, Bengtsson B, Persson A, Graffner H. Budesonide <i>versus<\/i> prednisolone in the management of Crohn\u2019s disease: a randomized multi-national 2-year study. <i>Gastroenterology<\/i>, <b>124<\/b>, A26 (2003).","DOI":"10.1016\/S0016-5085(03)80128-2"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Schoon EJ, Bollani S, Mills PR, Israeli E, Felsenberg D, Ljunghall S, Persson T, Hapt\u00e9n-White L, Graffner H, Bianchi Porro G, Vatn M, Stockbr\u00fcgger RW. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn\u2019s disease. <i>Clin. Gastroenterol. Hepatol.<\/i>, <b>3<\/b>, 113\u2013121 (2005).","DOI":"10.1016\/S1542-3565(04)00662-7"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Edsb\u00e4cker S, Larsson P, Bergstrand M. Pharmacokinetics of budesonide controlled-release capsules when taken with omeprazole. <i>Aliment. Pharmacol. Ther.<\/i>, <b>17<\/b>, 403\u2013408 (2003).","DOI":"10.1046\/j.1365-2036.2003.01431.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Sakurai Y, Mori Y, Okamoto H, Nishimura A, Komura E, Araki T, Shiramoto M. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects\u2014a randomised open-label cross-over study. <i>Aliment. Pharmacol. Ther.<\/i>, <b>42<\/b>, 719\u2013730 (2015).","DOI":"10.1111\/apt.13325"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/1\/48_b24-00435\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T03:27:24Z","timestamp":1737775644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/1\/48_b24-00435\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b24-00435","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"article-number":"b24-00435"}}